177 related articles for article (PubMed ID: 32498585)
1. Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.
Han BJ; Murphy JD; Qin S; Ye J; Uccello TP; Garrett-Larsen J; Belt BA; Prieto PA; Egilmez NK; Lord EM; Linehan DC; Mills BN; Gerber SA
Immunol Invest; 2020 Oct; 49(7):808-823. PubMed ID: 32498585
[TBL] [Abstract][Full Text] [Related]
2. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
5. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
6. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model.
Burrack AL; Rollins MR; Spartz EJ; Mesojednik TD; Schmiechen ZC; Raynor JF; Wang IX; Kedl RM; Stromnes IM
J Immunol; 2021 Mar; 206(6):1372-1384. PubMed ID: 33558374
[TBL] [Abstract][Full Text] [Related]
7. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.
Thomas SN; Vokali E; Lund AW; Hubbell JA; Swartz MA
Biomaterials; 2014 Jan; 35(2):814-24. PubMed ID: 24144906
[TBL] [Abstract][Full Text] [Related]
8. Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.
Fu EJ; Arca MJ; Hain JM; Krinock R; Rado J; Cameron MJ; Chang AE; Sondak VK
J Immunother; 1997 Mar; 20(2):111-22. PubMed ID: 9087383
[TBL] [Abstract][Full Text] [Related]
9. Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound.
Bugalho A; Martins C; Silva Z; Nunes G; Mendes AS; Ferreira I; Videira PA
Tumour Biol; 2016 Jan; 37(1):953-61. PubMed ID: 26264617
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
[TBL] [Abstract][Full Text] [Related]
11. Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy.
Liu Z; Yu Z; Chen D; Verma V; Yuan C; Wang M; Wang F; Fan Q; Wang X; Li Y; Ma Y; Wu M; Yu J
Cancer Commun (Lond); 2022 Oct; 42(10):971-986. PubMed ID: 35962977
[TBL] [Abstract][Full Text] [Related]
12. Lymph node targeting strategy using a hydrogel sustained-release system to load effector memory T cells improves the anti-tumor efficacy of anti-PD-1.
Cui H; Zhao YY; Han YH; Lan Z; Zou KL; Cheng GW; Chen H; Zhong PL; Chen Y; Ma LM; Chen TK; Yu GT
Acta Biomater; 2024 May; 180():423-435. PubMed ID: 38641183
[TBL] [Abstract][Full Text] [Related]
13. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
14. Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.
Bahmani B; Uehara M; Ordikhani F; Li X; Jiang L; Banouni N; Ichimura T; Kasinath V; Eskandari SK; Annabi N; Bromberg JS; Shultz LD; Greiner DL; Abdi R
EBioMedicine; 2018 Dec; 38():79-88. PubMed ID: 30497977
[TBL] [Abstract][Full Text] [Related]
15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
16. Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice.
Ye J; Suizu F; Yamakawa K; Mukai Y; Kato M; Yoneyama H; Yahagi N; Matsuda Y
Eur J Immunol; 2023 Sep; 53(9):e2250160. PubMed ID: 37248998
[TBL] [Abstract][Full Text] [Related]
17. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
[TBL] [Abstract][Full Text] [Related]
18. Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells.
Wang LK; Kuang M; Hua YP; He Q; Chen B; Wang Y; Peng BG
J Surg Res; 2013 Aug; 183(2):900-6. PubMed ID: 23481561
[TBL] [Abstract][Full Text] [Related]
19. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
20. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer.
Battaglia A; Buzzonetti A; Martinelli E; Fanelli M; Petrillo M; Ferrandina G; Scambia G; Fattorossi A
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1546-53. PubMed ID: 20338481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]